Royalty Pharma raises FY25 guidance to $3.2-$3.25 bln, Q3 receipts up 11% to $814 mln.

• Royalty Pharma reports Q3 2025 financial results • Portfolio Receipts up 11% to $814 million • Royalty Receipts up 11% • Net cash provided by operating activities: $703 million • Raised full year 2025 guidance for Portfolio Receipts • Expected to be $3,200 to $3,250 million • Increased Capital Deployment to $2.0 billion for the year